



Transmucosis to present its nasal vaccine platform at the 2024 World Vaccine Congress

- *Congress to be held Oct 29-31, 2024 in Barcelona, Spain*
- *Plenary presentation*

College Park MD, USA, 25 July 2024 – Transmucosis LLC (“Transmucosis” or the “Company”), a private biotechnology company pioneering a novel intranasal vaccine platform, today announces the Company’s participation in the World Vaccine Congress.

Dr. Andre Hoekema, Chief Business Officer, will provide a plenary session on “Effective nasal vaccination – enabling both mucosal and systemic immune response”. The presentation and discussion will focus on the dual action of the platform - a nasal IgA response plus a systemic T-cell and B-cell response. The presentation will highlight the preclinical proof of concept for protection against influenza and COVID-19 infection, and in particular the prevention of transmission of these viruses via the airways.

-ENDS-

For more information, please contact:

Transmucosis LLC

Herbert Heyneker, CEO

hheyneker@transmucosis.com

About Transmucosis

Transmucosis is a developer of protein-based intranasal vaccines against respiratory diseases. It leverages the unique properties of the FcRn receptor to facilitate the passage of nasal vaccines across the mucosal surface. Transmucosis developed multiple influenza vaccines. Furthermore, the company obtained preclinical proof of concept with intranasal vaccines against all tested strains of coronavirus, and against RSV. Transmucosis LLC was founded by Dr. Herbert Heyneker (CEO) and Prof. Dr. Xiaoping Zhu (CSO). Transmucosis signed an exclusive license agreement with the University of Maryland covering all research on the intranasal vaccine platform by the lab of Prof. Zhu’s. The lab has been funded for more than a decade by NIH and other grants. The company is located at 8075 Greenmead Drive, College Park, Maryland 20742-3711, USA.